Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Several outstanding health researchers in Oxford have been recognised in a prestigious national competition.

Image courtesy of Shutterstock

Eight people have been named National Institute of Health Research (NIHR) Senior Investigators in recognition of their “outstanding contribution to clinical and applied health and social care research”.

The successful candidates were all prominent researchers in the NIHR Oxford Biomedical Research Centre and the NIHR Oxford Health Biomedical Research Centre. The two institutions work in cooperation with each other, with the Oxford BRC focusing on a broad range of physical conditions, and the Oxford Health BRC concentrating on mental health and dementia.

Two other professors had their NIHR Senior Investigator awards renewed, while eight more who have previously held awards have now been designated Emeritus NIHR Senior Investigators.

Find out more (Oxford BRC website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.